Earnings Data
Report Date
Aug 10, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.75Last Year’s EPS
-0.85Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.Company Guidance
Strong Top-Line Revenue Growth
Total revenue for Q1 2026 was $191.2M, up 57% year-over-year, driven by growth in AUVELITY and SUNOSI and contributions from SYMBRAVO.
AUVELITY Commercial Performance
AUVELITY net product revenue of $153.2M in Q1 2026, up 59% YoY; more than 223,000 prescriptions in the quarter (+35% YoY); first-line/first-switch prescriptions increased to 56% of demand; ~60,000 unique prescribers since launch; commercial coverage 78% and total coverage 86% of lives.
Regulatory Milestone — New Indication for AUVELITY
FDA approval for AUVELITY for agitation associated with Alzheimer's disease (breakthrough therapy and priority review), making it a first-in-class option for a high-unmet-need population.
Updated AUVELITY Peak Sales Outlook
Company updated AUVELITY peak sales potential to at least $8 billion annual revenue at peak, with approximately equal contribution (~$4B) from MDD and Alzheimer's disease agitation.
SUNOSI and SYMBRAVO Momentum
SUNOSI net product revenue $33.9M in Q1 2026 (+34% YoY) with ~54,000 prescriptions (+16% YoY). SYMBRAVO showed launch momentum with ~17,000 prescriptions in the quarter and 36% growth vs Q4 2025.
Commercial Infrastructure Expansion
Expanded AUVELITY sales force to ~630 reps targeting ~68,000 HCPs; SYMBRAVO sales force expanded to ~150 reps; 5,500 new AUVELITY prescribers added in the quarter helping launch readiness for ADA indication.
Market Access Wins
SYMBRAVO secured a major commercial payer contract covering ~17 million lives; SUNOSI coverage steady at ~83% of lives; AUVELITY Medicare and Medicaid coverage at 100% in those channels.
Pipeline Progress and Business Development
NDA submitted for AXS-12 (cataplexy/narcolepsy); multiple Phase III trials starting in coming months (including solriamfetol programs, AXS-05 smoking cessation pivotal Phase II/III start); acquisition of AXS-20 (balipodect) added a PDE10A inhibitor with Phase III-enabling activities planned this year.
Balance Sheet and Cash Runway
Cash and cash equivalents $305M at quarter end (vs $323M year-end); company states cash sufficient to fund operations into cash flow positivity under current plan.
DE:19X Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:19X Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | €175.45 | €193.80 | +10.46% |
Feb 23, 2026 | €156.95 | €146.45 | -6.69% |
Nov 03, 2025 | €116.25 | €114.55 | -1.46% |
Aug 04, 2025 | €87.32 | €86.22 | -1.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Axsome Therapeutics Inc. (DE:19X) report earnings?
Axsome Therapeutics Inc. (DE:19X) is schdueled to report earning on Aug 10, 2026, Before Open (Confirmed).
What is Axsome Therapeutics Inc. (DE:19X) earnings time?
Axsome Therapeutics Inc. (DE:19X) earnings time is at Aug 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Axsome Therapeutics Inc. stock?
The P/E ratio of Axsome Therapeutics is N/A.
What is DE:19X EPS forecast?
DE:19X EPS forecast for the fiscal quarter 2026 (Q2) is -0.75.